Full Text of PDF (397k)
Article in Japanese
Abstract
Case Report
Successful alectinib rechallenge after drug-induced lung injury: a case report of Hanabiratake-induced interstitial lung injury
Fujihiro Kurea,b Yu Satoa,c Kengo Murataa Miyako Kitazonoa Akihiko Wadaa Mikio Takamoria
aDepartment of Respiratory Medicine and Medical Oncology, Tokyo Metropolitan Tama Medical Center
bDepartment of Respiratory Medicine, Funabashi Municipal Medical Center
cDepartment of Emergency and General Medicine, Tokyo Metropolitan Tama Medical Center
ABSTRACT
An 81-year-old male patient who received alectinib, a tyrosine kinase inhibitor (TKI), for lung adenocarcinoma developed lung injury. He was also taking Hanabiratake (Sparassis crispa), a type of edible fungus, as a dietary supplement. After all medicines and supplements including alectinib and Hanabiratake were stopped and corticosteroid was administered, the lung injury improved. A drug-induced lymphocyte stimulation test (DLST) was positive only for Hanabiratake, and the lung injury did not recur after resumption of alectinib administration. Based on these findings, drug-induced lung injury caused by Hanabiratake was diagnosed. Even when lung injury arises during treatment such as TKI therapy which often causes lung injury, it is still important to investigate possible causative agents including other medicines and supplements.
KEYWORDS
Drug-induced lung injury Sparassis crispa Alectinib Drug-induced lymphocyte stimulation test (DLST)
Received 25 Nov 2021 ／ Accepted 1 Mar 2023
AJRS, 12(3): 144-148, 2023
Copyright © The Japanese Respiratory Society All Rights Reserved.